[A24-123 ] Linzagolix (endometriosis) – Benefit assessment according to §35a Social Code Book V
Last updated 17.03.2025
Project no.:
A24-123
Commission:
Commission awarded on 16.12.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Reproductive health and birth
Symptomatic treatment of endometriosis in adult women of reproductive age with a history of previous medical or surgical treatment for their endometriosis; with concomitant hormonal add-back therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-123
| Project no. | Title | Status |
|---|---|---|
| A24-92 | Linzagolix (uterine fibroids) – Benefit assessment according to §35a Social Code Book V | Commission completed |